Fewer patients in the treatment group suffered Adults with stroke Total stroke Fatal or disabling stroke; Before the results of PROGRESS Costing combination therapy only (not single a stroke, and the risk of total major vascular or transient (fatal or total major vascular were published in 2001, there was therapy). events was also lower, irrespective of ischaemic attack = events (non-fatal stroke, little convincing evidence that Prevented vascular deaths preserve an patient’s blood pressure, type of initial event, time since 64,249, non-fatal MI, or death impaired life. treatment would reduce the last event, or geographic region. The trial due to any vascular incidence of recurrent stroke in Average cost of stroke treatment based on Proportion eligible provided evidence for blood pressure lowering cause); total and patients with cerebrovascular Tan Tanny et al. (2013). = 86% for the prevention of stroke particularly in specific deaths; and disease. those with known Cerebrovascular Disease hospital admissions. N = 55,254 irrespective of baseline blood pressure. Outcome Difference in N if Health Economic QALY Economic impact Total Economic Impact risk between service Impact on impact per on QALYS if control and at 65% cost per health service person implemented treatment person or costs if day implemented Primary Total stroke -44% -2,289 -$65,654 -$150m -$75,344 -$172m -$323m Secondary Non-fatal myocardial -41% -484 -$15,818 -$8m -$1,246 -$0.6m -$8m infarction Vascular death (excluding -22% -442 -$3,321 -$1m -$80,171 -$35m -$37m fatal stroke) Change in +$21m intervention costs Totals -$159m -$209m -$347m Columns may not sum due to rounding. Negative values are savings in the calculations. **Senior trial investigators have reported that per patient drug costs were covered by a commercial drug supplier. This was said to be $80m. If included, the net benefit of the PROGRESS study is $242m, and the consolidated BCR is 4:1. Health Health service/outcome Service or Explanation and costing assumptions Reference cost per person or Outcome day
Fewer patients in the treatment group suffered a stroke, and the risk of total major vascular events was also lower, irrespective of patient’s blood pressure, type of initial event, time since last event, or geographic region. The trial provided evidence for blood pressure lowering for the prevention of stroke particularly in those with known Cerebrovascular Disease irrespective of baseline blood pressure. Adults with stroke or transient ischaemic attack = 64,249, Total stroke (fatal or Fatal or disabling stroke; total major vascular events (non-fatal stroke, non-fatal MI, or death due to any vascular cause); total and deaths; and hospital admissions. Before the results of PROGRESS were published in 2001, there was little convincing evidence that treatment would reduce the incidence of recurrent stroke in patients with cerebrovascular disease. Costing combination therapy only (not single therapy). Prevented vascular deaths preserve an impaired life. Average cost of stroke treatment based on Tan Tanny et al. (2013). Proportion eligible = 86% N = 55,254 Outcome Difference in risk between control and treatment N if at 65% Health service cost per person or day Economic Impact on health service costs if implemented QALY impact per person Economic impact on QALYS if implemented Total Economic Impact Primary Total stroke -44% -2,289 -$65,654 -$150m -$75,344 -$172m -$323m Secondary Non-fatal myocardial infarction -41% -484 -$15,818 -$8m -$1,246 -$0.6m -$8m Vascular death (excluding fatal stroke) -22% -442 -$3,321 -$1m -$80,171 -$35m -$37m Change in intervention costs Totals +$21m -$159m -$209m -$347m Columns may not sum due to rounding. Negative values are savings in the calculations. **Senior trial investigators have reported that per patient drug costs were covered by a commercial drug supplier. This was said to be $80m. If included, the net benefit of the PROGRESS study is $242m, and the consolidated BCR is 4:1. Health Service or Outcome Health service/outcome cost per person or day Explanation and costing assumptions Reference specific